What is Diabeloop?
Diabeloop's core mission is to relieve people living with Type 1 diabetes from over 100 daily therapeutic decisions and reduce their significant mental burden. Originating from a medical research project, the company was established in 2015 by Dr. Guillaume Charpentier, who now serves as Chief Medical Officer. Erik Huneker has co-managed the company with Marc Julien since 2016. This leadership team collaborates with key partners like CEA-Leti, a prominent French technology research player, to advance its innovative solutions in diabetes management.
How much funding has Diabeloop raised?
Diabeloop has raised a total of $141.1M across 4 funding rounds:
Series A
$15.8M
Unspecified
$16.3M
Series B
$34M
Series C
$75M
Series A (2017): $15.8M with participation from Sofimac Investment Managers, Crédit Agricole CIB, and Kreaxi
Unspecified (2017): $16.3M, investors not publicly disclosed
Series B (2019): $34M supported by AGIR à dom, CEMAG, Odyssée Venture, and ADAG
Series C (2022): $75M featuring Innovacom, LBO France, and Terumo Corporation
Key Investors in Diabeloop
Innovacom
Innovacom is a seasoned investment firm with a strong track record in supporting digital startups, including those in medical imaging and high-potential technology sectors. Their involvement suggests a belief in Diabeloop's technological innovation and market potential.
LBO France
LBO France is a leading private equity firm with extensive experience in various investment activities, including digital health. Their participation highlights Diabeloop's maturity and potential for significant financial growth and operational value creation.
Terumo Corporation
Terumo Corporation is a global medical technology company. Their investment in Diabeloop signifies a strategic alignment in advancing diabetes care solutions and potentially integrating Diabeloop's technology within their broader healthcare offerings.
What's next for Diabeloop?
The substantial enterprise-level backing indicates Diabeloop is poised for significant scaling and further product development. This strategic investment will likely fuel advancements in their diabetes management technology, potentially expanding market reach and enhancing user experience. The company's trajectory suggests a focus on solidifying its position in the digital health sector, with future growth potentially involving broader clinical integration and international expansion.
See full Diabeloop company page
